Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05262400). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 235 participants (ACTUAL). Conditions: Breast Cancer, Solid Tumors. Interventions: DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion; DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion; DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation; DRUG: PF-07220060 + PF-07104091 combination dose escalation. Primary outcome measures: Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle , Cycle 1 (28 days); Number of participants with treatment emergent adverse events (AEs) , From baseline until end of study treatment or study completion (approximately 2 years); Incidence of participants with clinical laboratory abnormalities , From baseline until end of study treatment or study completion (approximately 2 years); Number of participants with vital signs abnormalities , From baseline until end of study treatment or study completion (approximately 2 years); Number of participants with corrected QT (QTc) interval , From baseline until end of study treatment or study completion (approximately 2 years). Brief summary: The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.